A
Astrid A.M. van der Veldt
Researcher at VU University Medical Center
Publications - 97
Citations - 2199
Astrid A.M. van der Veldt is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 21, co-authored 48 publications receiving 1863 citations. Previous affiliations of Astrid A.M. van der Veldt include VU University Amsterdam.
Papers
More filters
Journal ArticleDOI
Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
Astrid A.M. van der Veldt,Mark Lubberink,Mark Lubberink,Idris Bahce,Maudy Walraven,Michiel P. de Boer,Henri N.J.M. Greuter,N. Harry Hendrikse,Jonas Eriksson,Albert D. Windhorst,Pieter E. Postmus,Henk M.W. Verheul,Erik H. Serné,Adriaan A. Lammertsma,Egbert F. Smit +14 more
TL;DR: In NSCLC, bevacizumab reduced both perfusion and net influx rate of [(11)C]docetaxel within 5 hr and there was no evidence for a substantial improvement in drug delivery to tumors.
Journal ArticleDOI
Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
Nielka P. van Erp,Karel Eechoute,Astrid A.M. van der Veldt,John B. A. G. Haanen,An K.L. Reyners,Ron H.J. Mathijssen,Epie Boven,Tahar van der Straaten,Renee Baak-Pablo,Judith A.M. Wessels,Henk-Jan Guchelaar,Hans Gelderblom +11 more
TL;DR: This exploratory study suggests that polymorphisms in specific genes encoding for metabolizing enzymes, efflux transporters, and drug targets are associated with sunitinib-related toxicities.
Journal ArticleDOI
Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response
Astrid A.M. van der Veldt,Martijn R. Meijerink,Alfons J.M. van den Eertwegh,Axel Bex,Gijsbert C. de Gast,John B. A. G. Haanen,Epie Boven +6 more
TL;DR: Sunitinib can induce a significant reduction in volume of primary renal cell tumors and the role of nephrectomy before immunotherapy in patients with metastatic renal cell cancer will improve patient outcome.
Journal ArticleDOI
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib
Astrid A.M. van der Veldt,Karel Eechoute,Hans Gelderblom,Jourik A. Gietema,Henk-Jan Guchelaar,Nielka P. van Erp,Alfons J.M. van den Eertwegh,John B. Haanen,John B. Haanen,Ron H.J. Mathijssen,Judith A.M. Wessels +10 more
TL;DR: Genetic polymorphisms in three genes involved in sunitinib pharmacokinetics are associated with PFS in mRCC patients treated with this drug, and the findings advocate prospective validation and further elucidation of these genetic determinants in relation to sunit inib exposure and efficacy.
Journal ArticleDOI
Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c + Dendritic Cell Frequency Predicts Progression-Free Survival
Hester van Cruijsen,Astrid A.M. van der Veldt,Laura Vroling,Dinja Oosterhoff,Henk J. Broxterman,Rik J. Scheper,Giuseppe Giaccone,John B. A. G. Haanen,Alfons J.M. van den Eertwegh,Epie Boven,Klaas Hoekman,Tanja D. de Gruijl +11 more
TL;DR: The sunitinib-induced myeloid lineage redistribution observed in advanced RCC patients is consistent with an improved immune status and Immunologic recovery may contribute to clinical efficacy as suggested by the finding of highly increased MDC frequencies relative to other myeloids subsets in patients with tumor regression.